Assenagon Asset Management
KALA icon

Assenagon Asset Management’s KALA BIO KALA Stock Holding History

Assenagon Asset Management’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-143
Closed -$3.75M – 1240
2020
Q2 		$3.75M Buy
+143
New +$4.05M 0.02% 405

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management's KALA Position: Q3 2020 in Review

Assenagon Asset Management sold out of KALA BIO (KALA) in Q3 2020, closing a stake of 143 shares — an estimated $3.75M sold.

Assenagon Asset Management first reported a position in KALA in Q2 2020 and held it in 1 quarter. The position peaked at $3.75M in Q2 2020. 105 funds tracked by Wall St. Rank hold KALA as of Q3 2020.

  • Assenagon Asset Management reported no remaining KALA BIO position as of Q3 2020 after selling out during the quarter.
  • Assenagon Asset Management sold 143 KALA BIO shares in Q3 2020, an estimated $3.75M.
  • Assenagon Asset Management first reported a position in KALA BIO in Q2 2020 and held it in 1 quarter.
  • Assenagon Asset Management's KALA BIO position peaked at $3.75M in Q2 2020.
  • 105 funds tracked by Wall St. Rank held KALA BIO as of Q3 2020.

Based on Assenagon Asset Management's 13F filing for Q3 2020, filed 7 Oct 2020.